Figure 2.

Insulin-like growth factor-1 (IGF-1), thrombopoietin (TPO) and epinephrine rescue protease-activated receptor 1-mediated platelet function in the presence of antiplatelet compounds. Washed platelets (2 × 10⁸ mL⁻¹) were pretreated with vehicle control (HEPES–Tyrode buffer) (A) or inhibitors, i.e. 1 μm AR-C66096 (ARC) (B), 30 μm acetylsalicylic acid (ASA) (C), or ASA/ARC (D), as indicated for 10 min. Platelets were subsequently incubated in the presence of vehicle control or primer, i.e. 100 nm IGF-1 (Ai–Ei), 50 ng mL⁻¹ TPO (Aii–Eii), and 5 μm epinephrine (Aiii–Eiii), respectively, for 5 min before stimulation with 2 μm SFLLRN, and aggregation was recorded for 5 min. Representative aggregation traces (A–D) and quantified area under the curve analysis (E) are shown. Data are mean ± standard error of the mean, n = 6–8. Statistical analysis: two-way anova was used in conjunction with a Bonferroni post hoc test; *P < 0.05, **P < 0.01, ***P < 0.001.